Impact of A. Lumbricoides on Pulmonary Aspergillosis Development (NCT05783544) | Clinical Trial Compass
UnknownNot Applicable
Impact of A. Lumbricoides on Pulmonary Aspergillosis Development
Uzbekistan200 participantsStarted 2015-05-01
Plain-language summary
The prevalence of ascariasis in COPD patients with and without concomitant pulmonary aspergillosis and in controls will be determined. To assess the influence of ascaridosis on the development of pulmonary aspergillosis in COPD patients cytokine status of patients will be studied.
Who can participate
Age range
30 Years – 100 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* COPD patients
* COPD patients with aspergillosis
* COPD patients with ascariasis
* COPD patients with mix-infection
* Healthy individuals (controls)
Exclusion Criteria:
* COPD patients with other autoimmune diseases
* COPD patients with oncological diseases
* COPD patients with other co-infections
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Serum interleukin-1B levels in COPD patients and controls
Timeframe: up to 12 months
2
Serum interleukin-4 levels in COPD patients and controls
Timeframe: up to 12 months
3
Serum interleukin-6 levels in COPD patients and controls
Timeframe: up to 12 months
4
Serum tumor necrosis factor-a levels in COPD patients and controls
Timeframe: up to 12 months
5
Serum interferon-gamma levels in COPD patients and controls
Timeframe: up to 12 months
6
Correlation between cytokine status with chronic pulmonary aspergilosis insidence rate in COPD patients with and without ascariasis
Timeframe: up to 12 months
Trial details
NCT IDNCT05783544
SponsorResearch Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan